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ABSTRACT
Objective: To determine some virulent trait-related properties of poliovirus isolates
from children with acute flaccid paralysis following vaccination with oral polio
vaccine (OPV).
Design: Six polioviruses earlier characterised into wild, vaccine-derived and OPV-like
were studied using the plaque morphology and growth kinetics at supra-optimal
temperature.
Setting: Department of Virology, University of Ibadan, Nigeria.
Subjects: Polio isolates from six children who developed acute flaccid paralysis
following vaccinations with various doses of OPV were used. All the children were
located in the Northern part of the country where poliovirus is still circulating.
Main outcome measures: The two vaccine-derived polioviruses acquired wild type
characteristics.
Results: All the six poliovirus isolates developed different forms of plaques ranging
from tiny, small and large. The plaque formed could however not be used to identify
the different isolates. Growth of the different isolates at supra-optimal temperature
showed that the three wild polioviruses grew to a higher titre when compared with the
Sabin 2 control. The two vaccine derived isolates behaved like the wild poliovirus
while the OPV-like virus acquired an intermediate characteristics between wild and
sabin.
Conclusion: The wild polioviruses represented in this study are among the last vestiges
of the circulating polioviruses found in the world. It is possible that the observed
biological properties of wild types 1 and 3 described in the study are typical of the West
African polioviruses. These properties will provide useful previews to the final
identification of some important clinical isolates especially type 1 which may grow
rapidly in cell culture.
INTRODUCTION
When poliovirus is confined to the gut, it is harmless,
otherwise, it may induce paralysis following viraemia
and CNS invasion (1). This is usually the case for wild
poliovirus infection. However some live-attenuated
vaccine polioviruses that have re-acquired wild-like
properties following replication in human gut also
show neurovirulence like the wild strains (2) and are
excreted by oral polio vaccine (OPV) recipients (3).
Nigeria, which remains one of the last four
poliovirus endemic nations, uses the live-attenuated
trivalent OPV in routine vaccination of children and
in Supplementary Immunisation Activities (SIAs).
This has resulted in elimination of several genetic
lineages of wild polioviruses in Nigeria though the
138 EAST AFRICAN MEDICAL JOURNAL March 2008
OPV coverage has not been high enough to get rid of
the last reservoirs of the virus. Globally, as the
circulation of wild polioviruses is decreasing, vaccine-
derived polioviruses,(VDPV) as well as, OPV-like
viruses associated with paralytic poliomyelitis,
although rare, are causing increasing concern.
Poliovirus is among the most rapidly evolving
viruses known, with about one percent nucleotide
substitution per site per year (4). Therefore, OPV
recipients usually excrete altered vaccine viruses
after vaccination (3). Acquired alterations in the base
sequence of the altered vaccine viruses may change
their degree of attenuation (5) as well as, their
temperature sensitivity(ts) (2). All the three Sabin
strains are temperature-sensitive, producing lower
virus yields at supra-optimal temperatures than the
wild poliovirus (6). Loss of attenuation (3) and
temperature sensitivity (7) by derivatives of OPV
strains excreted by OPV recipients differentiate them
from their corresponding attenuated and temperature
sensitive Sabin virus strains (2). The development of
techniques for growing polioviruses in tissue culture
allowed the recognition of certain characteristics of
clonal virus population that can serve as markers for
attenuation and as differentiation between wild-type
and attenuated Sabin vaccine viruses (8).
Plaque morphology of viruses had been
correlated with virulence (9) while temperature
sensitivity and plaque formation in tissue culture
have been used to determine the degree of attenuation
and neurovirulence of poliovirus isolates (7). This
study was carried out to determine some biological
and plaque properties of these selected polio viruses
which were isolated from acute flaccid paralysis
patients vaccinated with the oral polio vaccine(OPV).
MATERIALS AND METHODS
The details of the subjects and the polio viruses used
in the study are provided in Table 1.
Table 1
History of poliovirus isolates
Isolated from
S/N Virus ID Lab ID Age Sex Location Vac. history Type Results of 60
(Months) day follow-up
1. 3D REC2/0455 IBD/02/0455 21 M Plateau 3 doses of OPV 2 NPC
2 VD2/0119 IBD/01/0119 16 M Bauchi 2 doses of OPV 2 PC
3. WP1/898 IBD/03/899 12 F Kebbi 4 doses of OPV 1 PC
4. WP1/007 IBD/02/007 23 M Kaduna 2 doses of OPV 1 PC
5. WP3/230 IBD/02/230 12 F Abuja 5 doses of OPV 3 PC
6. OPV2/098 IBD/02/098 16 F Kwara 3 doses of OPV 2 PC
ID = Identity, NPC = Non - Polio Compatible, PC = Polio Compatible, VD = Vaccine - derived,WP = Wild
poliovirus, OPV = Oral Polio Vaccine-like virus, 3D Rec= 3D Recombinant
Viruses: The six polioviruses used in this study were
categorised into three groups: wild type, vaccine
derived and OPV- like sabin. All the viruses were
isolated from the stool of children who developed
various degrees of acute flaccid paralysis following
vaccination with various doses of the OPV. Virus
REC2/0455 was initially detected as a SL like virus
by ELISA but was found to be an abnormal Sabin
using the REC primers developed by Kilpatrick et al
(l0). Sequence result showed a two nucleotide changes
in the VP1 but a vaccine/non-vaccine recombinant in
the 3D region (11). Virus VD2/0119 was a VDPV
with 22 nucleotide changes in the VPI capsid region
and HEV- C enterovirus combination in the 5'-UTR
and 3D non-capsid region (l2). Isolates WPI/898,
WPI/007 and WP3/230 were identified as wild
poliovirus types 1 and 3 respectively while isolate
OPV2/098 was identified as a sabin-like polio virus.
Viruses were initially isolated and identified as polio
viruses at the WHO National Polio Laboratory, Ibadan
according to WHO recommended procedures (13)
and intra-typically differentiated as earlier described
(9,20). The intratypic typing ( ITD ) which identified
the isolates as either Sabin, or wild- type was done at
the WHO Regional Laboratory, Ghana using the
ELISA method, with cross-adsorbed type-specific
polyclonal antibodies (14) while the sequencing was
done at the WHO special Polio Laboratory at the
Centres for Disease Control, Atlanta, USA, using
Sabin-specific primers (15,16). The isolates were
recovered from the Ibadan laboratory for the present
study.
Reference Sabin-2 strain: This control virus was
the live-attenuated Sabin vaccine poliovirus type 2
(Sabin-2) from National Institute of Biological
Standard and Control (NIBSC), London, England,
with reference number 01/530. This reference Sabin-
2 strain had been stored at -20°C.
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Cells: The three cell lines used in this study were
HEp-2C (human larynx carcinoma), L20B (murine L
cells expressing human poliovirus receptor), and RD
(human rhabdomyosarcoma) cell lines. All the cells
were supplied by WHO to the polio laboratory
network.
Virus stock: Preparations of poliovirus stocks were
done according to standard procedure for virological
investigation of poliovirus (l8). Viruses were passaged
in monolayers of L20B cells and RD cells to produce
high-titre viruses for this study. Each virus stock was
stored at -20°C.
Plaque assays: Plaque assay was done in HEp-2C cell
monolayers at 37°C as described by Burleson et al (l7).
Phenotypic study of plaques and determination of plaque
titres: The plaque morphology was visually observed
and scored for such characteristics like size; nature of
plaque centre and the nature of plaque edges. Plaque
size was determined by measuring the cross-diameter
of each discrete plaque with a 30 centimetre-rule.
Plaque sizes were recorded in millimetres (mm).
Plaque titre for each poliovirus isolate was calculated
as described by Burleson et al ( 17).
One-step growth curves: The growth rates of all the
isolates at 39.5°C in HEp-2C cells were compared
with that of Sabin-2 virus in one-step growth
experiments at a multiplicity of infection of five
plaque-forming units/cell in tissue culture tubes as
described by Burleson, et al (17). Titres of virus samples
were determined by 50%. Tissue Culture Infective
Dose (TCID50/ml) in L20B cells incubated at 37°C as
described earlier (17).
RESULTS
Virus stock: All the viruses grew to appreciable plaque-
forming unit titres in HEp-2C cells after passaging in
L20B and RD cell lines. Titres ranged between 6.3 x
106 to 2.1x 108. These titres were used for the plaque
and the growth characteristics.
Plaque characteristics of the virus isolates: The plaque
characteristics of the poliovirus isolates are as shown
in Table 2. The average plaque diameter ranged
between 0.9mm and 3.6mm. Plaque morphologies
were of various types- tiny, small and large with
either clear centres or serrated edges.
One-step growth curves of the isolates: The one-step
growth curve is shown in Figure 1. The wild polio
viruses grew to higher titres (range Log 105.8-Log
109.3) when compared with the Sabin 2 control with
titre range between Logl04.8 to Log 107.8 after eight
hours at 39.5°c. The two vaccine derived isolates
behaved in their growth at 39.5°c like the wild isolates
while the OPV isolate acquired a growth characteristic
that was intermediate between the wild and the
Sabin 2 control.
Figure 1
One-step growth curve of polioviruses isolated from acute flaccid paralysis cases
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DISCUSSION
As part of her effort to stop the transmission of the
circulating wild poliovirus, Nigeria had embarked
on mass and intensive use of the oral polio vaccine
(OPV) during National Immunisation Days (NIDs)
as well as during Sub-National Immunisation
Days(SNIDs). However wild poliovirus has
continued to circulate in Nigeria. Many factors, of
which low population immunity had been identified,
is responsible for the continous circulation of these
wild polioviruses and rapid evolution and spread of
revertant polioviruses (3). In this study we had
attempted to determine some phenotypic virulent
traits that must have been responsible for the
behaviour of some wild poliovirus and revertant
isolates by characterising their plaque and growth
kinetics.
Assessment of the temperature sensitivities of
all the wild-type isolates revealed that they were
heat-stable at 39.5°C in HEp-2C cell line unlike the
reference Sabin-2 virus. Two of the isolates -VD2/
0455 and VD2/0119 which had some significant
changes in their nucleotide sequences(ll,l2) were
similar to the wild viruses in their insensitivity to the
elevated temperature. They all grew rapidly to high
titres right from zero to eight hour period while the
reference Sabin 2 strain exhibited a marked sensitivity
to this elevated temperature (Figure l). This is in
agreement with the findings of Yang, et al. (2) who
observed some degree of loss of temperature
sensitivity for some vaccine-derived polioviruses
from polio cases in Egypt. The behaviour of these two
isolates is an indication of some loss of some degree
of attenuation during replication as evidenced by the
fact that two substitutions associated with the
attenuated phenotype had either recombined out
(A48l →G in the 5'-UTR) or reverted (Ilel43 →Thr in
VPI) in both these two isolates(l2).
When changes in the OPV viruses resulted in
re-acquisition of transmissibility and neurovirulence,
like their wild counterparts (2,18) they may induce
paralytic disease called vaccine-associated paralytic
poliomyelitis (VAPP) in OPV recipients and in their
susceptible contacts (19). Such vaccine poliovirus
strains have been reported as the cause of VAPP
outbreaks in different places(20).
The current reinvestigation of the growth
properties of different poliovirus isolates may have
broader applicability than the earlier studies because
the wild polioviruses represented in this study are
among the last vestiges of the circulating polio viruses
found in the world. It is therefore possible that the
observed biological properties of the wild type 1 and
3 isolates described in Table 2 are typical of the West
African polioviruses. These properties will definitely
provide some useful previews to the final
identification of some important clinical isolates
especially for type 1 wild polioviruses, which may
grow rapidly in cell culture. It is also possible that the
more vigorous growth of the wild type 1 polioviruses
when compared to the wild type 3 polioviruses could
account partly for the wider geographical distribution
of wild type 1 poliovirus. It was also interesting that
the divergent type 2 vaccine-derived poliovirus grew
better than Sabin 2 or the other type 2 vaccines related
polioviruses in this study.
The OPV-like isolate showed a similarity in its
temperature sensitivity to the Sabin 2 virus only in
the first three hours of replication at 39.5°C, after
which it lost temperature sensitivity and behaved
like the wild and the vaccine- derived isolates. This
behaviour might  be unconnected with its association
with the AFP case which was later confirmed to be
polio compatible by the 60- day follow-up. In contrast
to the findings of Yang, et al (2) who reported that
OPV- like isolate was temperature sensitive at 39.5°C
in BGM and HeLa cells respectively, the reason for
loss of temperature sensitivity of OPV2/098 observed
in this study may be due to some mutational changes
in the sequence. It will therefore be interesting to
sequence this isolate for further understanding.
Table 2
Plaque titres and morphology of polioviruses at 37°C in HEp-2C cell monolayer
Average HEp-2C Average plaque              Other plaque features
Poliovirus plaque titre diameter (mm)
(PFU/ml)
3D Rec/0455 3.4 x 107 1.9 Mixture of tiny and small plaques with clear centre
 and serrated edges
VD2/0119 6.3 x 106 1.1 Tiny plaques with clear centres
WP1/899 2.1 x 108 3.6 Large plaques with serrated edges and centre
WP1/007 1.3 x 108 3.6 Large plaques with serrated edges and centre
WP3/230 1.4 x 107 1.0 Tiny plaques with clear centre
OPV2/098 3.3 x 107 0.9 Tiny plaques with clear centre
Sabin 2 7.5 x 106 1.1 Tiny plaques with clear centre
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Both the VD2/0119 and VD/0455 exhibited
two types of plaque morphology. While VD2/0119
exhibited tiny plaques similar to the WP3/230 wild
isolate, the VD2/0455 showed a mixture of small and
tiny plaques. The behaviours of these two viruses in
their plaque morphology may be unconnected with
changes they sustained in their genomes, the VD2/
0119 had three nucleotide changes in its VP1 region,
while VD2/0455 had 22 nucleotide changes in its VPl
region (11,12). The case with which VD2/0119 was
associated was non-polio compatible as there was no
residual paralysis. Though the VD2/0119 vaccine-
derived virus actually evolved in the course of
replication in GIT of the vaccinee, it could be suggested
that it did not evolve towards neuropathogenicity of
the wild type, as once observed by Georgescu, et al
(4) and Martin, et al (l9). This might be the reason for
the non-polio compatibility of the case. Also, since
none of these two viruses showed large plaques, it
may be suggested that the mutations they sustained
only influence temperature sensitivity, but did not
enhance their replication competence. The different
polioviruses irrespective of their plaque phenotypes
exhibited different degrees of paralysis in the patients.
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